Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The effect of silymarin on diabetes mellitus-induced male rats reproductive impairment: Evidences for role of heat shock proteins 70 and 90.

Polish journal of veterinary sciences·2024

Same author

Treatment of Obesity with Thyroid hormones in Europe. Data from the THESIS* Collaboration.

Journal of endocrinological investigation·2024

Same author

[Guideline for Radioiodine Therapy for Benign Thyroid Diseases (6/2022 - AWMF No. 031-003)].

Nuklearmedizin. Nuclear medicine·2023

Same author

Evaluation of Autophagy Process in Differentiation of Human Induced Pluripotent Stem Cells toward Insulin Producing Cells.

International journal of organ transplantation medicine·2023

Same author

Focus on radioiodine-131 biokinetics: the influence of methylprednisolone on intratherapeutic effective half-life of <sup>131</sup>I during radioiodine therapy of Graves' disease.

Endocrine·2021

Same author

Longer-term recurrence rate after low versus high dose radioiodine ablation for differentiated thyroid Cancer in low and intermediate risk patients: a meta-analysis.

BMC cancer·2020

Same journal

Tirzepatide as a multi-organ integrator in metabolic diseases: a review of molecular mechanisms and clinical translation.

Endocrine·2026

Same journal

Effects of a single-dose denosumab on glucose and lipid homeostasis in young infertile men.

Endocrine·2026

Same journal

Ultrasound-guided thermal ablation for papillary thyroid microcarcinoma with calcifications: short-term imaging outcomes.

Endocrine·2026

Same journal

Diabetic gastroparesis: pathophysiology and impact on insulin timing choices.

Endocrine·2026

Same journal

Liquid biopsies for BRAF V600E assessment and monitoring in anaplastic thyroid carcinoma: a real-world study of a tertiary cancer center.

Endocrine·2026

Same journal

Interpreting the TIR 3B nomogram as a rule-in rather than rule-out tool.

Endocrine·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Dec 26, 2025

Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System

Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System

Published on: April 11, 2018

Correction for hyperfunctioning radiation-induced stunning (CHRIS) in benign thyroid diseases.

C Happel¹, W T Kranert², D Gröner²

¹Department of Nuclear Medicine, University Hospital, Goethe University, Frankfurt, Theodor Stern Kai 7, D-60590, Frankfurt, Germany. Christian.Happel@kgu.de.

|March 17, 2020

Summary

This summary is machine-generated.

Radioiodine-131 therapy for thyroid conditions can be improved by accounting for the "stunning phenomenon" with new correction factors. This enhances treatment precision for goiter and multifocal autonomous nodules by calculating individualized radioiodine activity.

Keywords:

Benign thyroid disease CHRIS Radioiodine therapy Stunning Thyroid

More Related Videos

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Monitoring Blood-Brain Barrier Opening in Rats with a Preclinical Focused Ultrasound System

Monitoring Blood-Brain Barrier Opening in Rats with a Preclinical Focused Ultrasound System

Published on: September 13, 2024

Related Experiment Videos

Last Updated: Dec 26, 2025

Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System

Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System

Published on: April 11, 2018

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Monitoring Blood-Brain Barrier Opening in Rats with a Preclinical Focused Ultrasound System

Monitoring Blood-Brain Barrier Opening in Rats with a Preclinical Focused Ultrasound System

Published on: September 13, 2024

Area of Science:

Nuclear medicine
Endocrinology
Medical physics

Background:

Radioiodine-131 (I-131) is a long-established treatment for benign thyroid diseases.
The "stunning phenomenon," characterized by reduced radioiodine uptake after diagnostic administration, impacts treatment efficacy.
The precise physiological mechanisms of thyroid stunning remain under investigation.

Purpose of the Study:

To develop dose-dependent correction factors to address the stunning phenomenon in I-131 therapy.
To improve the precision of radioiodine treatment for goiter and multifocal autonomous nodules.
To establish a method for calculating stunning-independent radioiodine activity.

Main Methods:

Retrospective analysis of 313 patients undergoing I-131 uptake testing and treatment.
Modification of the Marinelli equation using indication-specific stunning values (8.2%/Gy for nodules, 21%/Gy for goiter).
Development and application of correction factors for hyperfunctioning radiation-induced stunning (CHRIS) to re-evaluate I-131 dosimetry.

Main Results:

CHRIS-modified Marinelli equations were developed for goiter and multifocal autonomous nodules.
CHRIS calculations significantly improved the fluctuation range of radiation dose delivery in target volumes for both conditions.
For multifocal autonomous nodules, CHRIS yielded a significantly higher mean administered dose (150 Gy) compared to conventional methods (131 Gy).

Conclusions:

The CHRIS equation enables the calculation of individualized, stunning-independent radioiodine activity using uptake testing data.
This approach enhances the understanding of thyroid stunning in benign thyroid diseases.
The CHRIS method improves the precision of radioiodine-131 dosimetry for goiter and multifocal autonomous nodules.